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Abstract
Neuroblastoma (NB) is the most commonly occurring solid tumor in children. The disease usually arises in the
adrenal medulla, and it is characterized by a remarkable heterogeneity in its progression. Most NB patients with
an advanced disease have massive bone marrow infiltration at diagnosis. Lung metastasis represents a widely
disseminated stage and is typically considered to be a terminal event. Much like other malignancies, NB progres-
sion is a complex, multistep process. The expression, function, and significance of the various factors involved in
NB progression must be studied in relevant in vivo and in vitro models. Currently, models consisting of metastatic
and nonmetastatic cell variants of the same genetic background exist for several types of cancer; however, none
exists for NB. In the present study, we describe the generation of a NBmetastasis model. SH-SY5Y andMHH-NB-11
NB cells were inoculated orthotopically into the adrenal glands of athymic nude mice. Neuroblastoma cells me-
tastasizing to the lungs were isolated from mice bearing adrenal tumors. Lung metastatic variants were generated
by repeated cycles of in vivo passage. Characterization of these variants included cellular morphology and immu-
nophenotyping in vitro, aggressiveness in vivo, and various biologic parameters in vitro. The NB metastatic variant
in each model displayed unique properties, and both metastatic variants demonstrated a metastatic phenotype
in vivo. These reproducible models of human NB metastasis will serve as an unlimited source of transcriptomic
and proteomic material. Such models can facilitate future studies on NB metastasis and the identification of novel
NB biomarkers and targets for therapy.
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Introduction
Neuroblastoma (NB) is a sympathetic nervous system malignancy
that accounts for approximately 8% of malignancies in patients
younger than 15 years. This tumor originates from the embryonic
neural crest, and it occurs most commonly in the adrenal gland [1].
Children older than 1 year of age, with a widespread metastatic
disease or with a large, aggressive, localized tumor, have a poor
long-term survival rate of approximately 30% [2,3]. The NB dissem-
inates either by hematogenous spread, producing metastasis most fre-
quently in bone marrow, bone, liver, and skin, or by lymphatic spread
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to regional and distant lymph nodes [4,5]. Lung metastases are con-
sidered a terminal event representing a widely disseminated meta-
static disease [6–8].
Metastasis is a highly selective and sequential process that requires
the coordinated action of many genes. This process includes loss of
cellular adhesion, increased motility and invasiveness, entry and sur-
vival in the circulation, exit into new tissue, and eventual coloniza-
tion of a distant site [9–11]. The outcome of this process depends on
both the intrinsic properties of the tumor cells and the organ micro-
environment [11,12].
In vitro and in vivo models for NB metastasis are essential for stud-
ies dealing with all aspects of this process and for the design of novel
cancer therapy modalities [13–17]. A model that comprises meta-
static and nonmetastatic cell variants originating from the same pri-
mary tumor would facilitate the identification of genes and gene
products linked to metastasis. Such variants have a common genetic
background but may differ in the metastasis-associated genetic signa-
ture. Whereas such models exist for several types of cancer including
colorectal carcinoma, pancreatic carcinoma, squamous cell carcinoma,
hepatocellular carcinoma, and lung cancer [18–22], none exist thus
far for NB.
Ongoing studies in our laboratory deal with site-specific metastasis
of NB and focus on the cross talk between these tumor cells and
components of their microenvironment and on the downstream ef-
fects of such interactions. To facilitate such studies, we set out to de-
velop an orthotopic mouse model for human NB metastasis. The
orthotopic implantation of the SH-SY5Y and MHH-NB-11 human
NB cell lines into the adrenal gland of nude mice yielded local tu-
mors as well as lung metastases. This study describes the in vivo es-
tablishment of local tumor and metastatic variant lines from these
tumors and their initial characterization.
Materials and Methods
Animals
Male athymic nude mice (BALB/c background) were purchased
from Harlan Laboratories Limited (Jerusalem, Israel). The mice were
housed and maintained for approximately 6 months in laminar flow
cabinets under specific pathogen-free conditions in the animal quar-
ters of Tel-Aviv University and in accordance with current regulations
and standards of the Tel-Aviv University Institutional Animal Care
and Use Committee. The mice were used in accordance with insti-
tutional guidelines when they were 7 to 10 weeks old.
Human NB Cell Lines and Culture Conditions
The SH-SY5Y [23] cell line was purchased from the American
Type Culture Collection (Rockville, MD), and the MHH-NB-11
[24] cell line was kindly provided by Dr. T. Pietsch, Department
of Neuropathology, University of Bonn Medical Center, Bonn, Ger-
many. All human NB cells were maintained as monolayer cultures in
growth medium: RPMI 1640 medium supplemented with 10% fe-
tal calf serum (FCS), 100 U/ml streptomycin, 12.5 U/ml nystatin,
100 U/ml penicillin, and 2 mM L-glutamine (all materials were pur-
chased from Biological Industries, Beit Ha’emek, Israel). The cultures
were incubated at 37°C in a mixture of 6.5% carbon dioxide. The
cultures were tested and found to be free ofMycoplasma. The cultures
were maintained for no longer than 9 weeks after recovery from fro-
zen stocks.
Orthotopic Inoculation of Tumor Cells
For in vivo inoculation, cells were harvested and transferred to
RPMI 1640 medium supplemented with 5% FCS. Only single-cell
suspensions of greater than 90% viability (trypan blue exclusion)
were used for injection.
Anesthesia was induced by ketamine (100 mg/kg body mass; Kepro
Deventer, The Netherlands) and 2% xylazine (10 mg/kg body mass;
Medical Market, Tel Izhak, Israel) administered intraperitoneally. Tu-
mor cells (1 × 106/50 μl) were injected orthotopically into the ad-
renal gland. This injection required surgical exposure of the left
adrenal gland under anesthesia. Briefly, a left-side high-paracostal ap-
proach to the abdomen allowed visualization of the cranial tip of the
left kidney. A 27-gauge needle was introduced through the left ad-
renal fat pad into the adrenal gland after retraction of the left kidney.
The skin was closed by surgical stitching.
Necropsy Procedure and Histopathologic Studies
Mice were killed, and local (adrenal) tumor, lung, sternum, and
other peritoneal organs suspected to hold metastases were harvested.
Lung and sternum were fixed in 4% buffered formalin (Bio-Lab
Ltd., Jerusalem, Israel), embedded in paraffin, and sectioned. Sec-
tions were stained with hematoxylin and eosin and were evaluated
by light microscopy for the presence of metastases.
In Vivo Generation of Metastatic Variants from SH-SY5Y and
MHH-NB-11 Human NB Cell Lines
SH-SY5Y or MHH-NB-11 cells (1 × 106) were injected into the
adrenal gland of nude mice. Local adrenal tumors, which appeared at
the site of inoculation as well as in organs such as liver, bone marrow,
and lung, suspected to harbor metastases were harvested, minced to
pieces, and cultured in vitro. Primary cultures were passaged in vitro
for three to five times. Cells harvested from these cultures were in-
jected into the adrenal gland of another set of nude mice.
In the first in vivo cycle, NB cells were isolated from local adrenal
tumors (designated as SY5Y.Ad or MHH.Ad cell variants) as well as
from lung. Isolated NB cells from the lung were reinjected into the left
adrenal gland of another set of nude mice. The inoculation of NB cells
from the adrenal gland to lung was repeated two and three times to
yield cell variants designated as SY5Y.Lu2 and MHH.Lu3, respectively.
Antibodies
The following antibodies were used for flow cytometry: phycoerythrin-
conjugated mouse anti–human CD56 mAb (DakoCytomation,
Glostrup, Denmark); rabbit anti–human CX3CL1 polyclonal anti-
body, 1 μg/sample (Torrey Pines Biolabs, Inc., East Orange, NJ);
rabbit anti–human CX3CR1 polyclonal antibody, 1 μg/sample (eBio-
science, San Diego, CA); anti–human CXCR3 mAb, 2.5 μg/sample
(clone 49801), anti–human TrkA mAb, 0.25 μg/sample (clone
165131), anti–human TrkB mAb, 0.25 μg/sample (clone 72509),
anti–human MRP1 mAb (clone QCRL; all from R&D, Systems
Inc., Minneapolis, MN); anti–human CD44 polyclonal antibody,
0.25 μg/sample (BioLegend, San Diego, CA); and anti–human
CXCR4 mAb, 0.5 μg/sample (CD184, clone B-R24; Diaclone, Stam-
ford, CT). Anti–HLA-A, -B, and -C mAb (W6/32) [25] and anti–
H-2 mAb (20-8-4S) [26] were kindly provided by Dr. R. Ehrlich,
Department of Cell Research and Immunology, Tel-Aviv University,
and were used at the dilutions of 1:500 and 1:3000, respectively, for
flow cytometry. Fluorescein isothiocyanate (FITC)–conjugated goat
antimouse IgG and goat antirabbit IgG (Jackson ImmunoResearch
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Laboratories, West Grove, PA) were used at the dilution of 1: 50 as
secondary antibodies for flow cytometry.
Affinity-purified goat anti–human hypoxia-inducible factor 1 al-
pha (HIF-1α) polyclonal antibody (R&D Systems, Inc.) and anti–
human ERK 2 polyclonal antibody (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) were used for Western blot analysis at the dilution
of 1:1000. The anti–human matrix metalloproteinase 2 (MMP-2)
mAb and anti–human MMP-9 mAb were used for Western blot
analysis at 1 μg/ml (EMD Chemicals, Inc., San Diego, CA).
Horseradish peroxidase–conjugated goat antimouse antibodies and
rabbit antigoat antibodies were used according to the manufac-
turer’s instructions (Jackson ImmunoResearch Laboratories).
Flow Cytometry
Double staining. For the double staining procedure, the cells
(0.5–1 × 106) were washed with FACS medium (RPMI 1640 sup-
plemented with 5% FCS and 0.01% sodium azide). The samples
were incubated for 1 hour at 4°C with the relevant primary antibody.
After a wash with FACS medium, the cells were incubated for 1 hour
at 4°C with FITC-conjugated secondary antibody. After another
wash with medium, the cells were incubated for 1 hour at 4°C with
a relevant antibody (conjugated with phycoerythrin). After an ad-
ditional wash, antigen expression was determined using FACSort
(Becton Dickinson, Mountain View, CA) and CellQuest software.
Baseline staining was obtained by labeling the cells with secondary
antibodies alone.
Single staining. Neuroblastoma cells were cultured for 24 hours in
growth medium containing 10% FCS. Cells (0.5–1 × 106) were in-
cubated for 1 hour at 4°C with relevant primary antibody. After a
wash with FACS medium, the cells were incubated for 1 hour at
4°C with FITC-conjugated secondary antibody. After an additional
wash, antigen expression was determined using Becton Dickinson
FACSort and CellQuest software. Baseline staining was obtained
by labeling the cells with secondary antibodies alone. For intracellular
staining of MRP-1, cells were incubated with absolute methanol at
−20°C for 30 minutes and then rinsed twice with FACS medium
before the staining procedure. Statistical analysis was performed using
Student’s t test.
Cytogenetic Analysis
Chromosome spreads were prepared according to conventional cy-
togenetic techniques. Multiplex fluorescence in situ hybridization
analysis for 24-color karyotyping was performed according to the
manufacturer’s protocols (Meta Systems GmbH, Altlusshein, Ger-
many). Multiplex fluorescence in situ hybridization signals were vi-
sualized using a fluorescence microscope (AxioImager Z.1; Zeiss,
Göttingen, Germany) and analyzed using Isis-366 software.
Wound Healing Assay
The wound healing assay was performed in cells growing in 24-
well plates coated with 5 to 10 μg/ml fibronectin (Biological Indus-
tries). Upon confluency, the cell monolayer was wounded with a
plastic tip, then washed twice with RPMI medium, and replaced
with a fresh growth medium. Closure of the denuded area was mon-
itored using an inverted microscope (Eclipse TE 2000-S; Nikon, En-
field, CT) fitted with a digital camera (DXM1200F; Nikon). Photo
documentation was taken at days 1, 2, 3, and 4 after the wounding.
Hypoxia Mimetic Assay
Neuroblastoma cells (2 × 106) were plated in growth medium. Af-
ter an overnight incubation, the medium was replaced with fresh
growth medium supplemented with 0, 25, and 50 μM deferoxamine
mesylate salt (DFX; Sigma, St. Louis, MO). After 24 hours of incu-
bation, nonadherent and adherent cells were pelleted and lysed with
RIPA buffer [20 mM Tris, pH 8, 150 mM NaCl, 1% NP-40 (Sigma),
0.1% SDS, 0.75% deoxycholate, 5 mM EDTA, pH 8, 3 mM EGTA,
pH 8, 20 mM sodium phosphate, pH 7.6, 2 mM sodium orthovan-
adate, 5 mM NaF, 5 mM sodium pyrophosphate, pH 7.6, 2 ng/ml
aprotinin, 2 ng/ml leupeptin, and 1 mM PMSF (Sigma)]. Samples
were used for the detection of HIF-1α by Western blot analysis.
Gelatin Substrate Zymography
Neuroblastoma cells were plated in growth medium. The growth
medium was removed after overnight incubation and was replaced by
serum-free RPMI for an additional 24 hours. Matrix metalloprotein-
ases production in the conditioned medium was determined by sep-
aration on 7.5% SDS–polyacrylamide gels (PAGE) containing 0.1%
gelatin substrate. After electrophoresis, gels were washed three times in
50 mM Tris–HCl, pH 7.4, containing 2.5% Triton X-100. The gels
were then washed three times in 50 mMTris–HCl buffer, pH 7.4, fol-
lowed by incubation in an incubation buffer, consisting of 50 mM
Tris–HCl, pH 7.4, 0.02% sodium azide, and 10 mM CaCl2 for
48 hours at 37°C. After three washes in double-distilled H2O,
the gels were stained with 0.25% Coomassie blue and destained
in 20% methanol and 10% glacial acetic acid, and then clear bands
of protein degradation were visualized.
Western Blot Analysis
Conditioned medium samples that were used in the gelatin sub-
strate zymography assay were resolved on SDS-PAGE and transferred
onto a 0.45-μm polyvinylidene fluoride membrane (Millipore, Bedford,
MA). For the hypoxia mimetic assay, cell lysates were incubated for
15 minutes on ice and cleared by centrifuging at 16,000g for 20 min-
utes at 4°C. After the addition of Laemmli sample buffer, the lysates
were boiled for 10 minutes, resolved on SDS-PAGE, and transferred
onto nitrocellulose membrane. After the transfer, the membrane was
incubated at room temperature with 5% dry milk in TBS–Tween
for 1 hour to block free binding sites on the membrane. The pro-
teins of interest were detected by specific antibodies. The proteins
were visualized on film using ECL (Amersham Pharmacia Biotech,
Buckinghamshire, England).
Proliferation In Vitro and Viability Assays
Neuroblastoma cells were harvested from 80% confluent mono-
layer cultures. The cells were seeded at a density of 1 × 104 to 105
cells per well in a 96-well flat-bottomed tissue culture plate. After
24 hours of incubation, the indicated concentrations of doxorubicin
hydrochloride, Dox (Sigma), or DFX were added to the wells. Prolif-
eration and viability under normal conditions or after Dox treatment
were monitored in quadruplicates after 0, 24, 48, 72, and 96 hours
with an XTT-based assay according to the manufacturer’s instruc-
tions (Biological Industries). Cell proliferation after DFX treatment
was estimated in duplicates after 24 hours using the XTT assay. Ab-
sorbance at 450 nm (OD450) was determined for each well using
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an automated microplate reader (SpectraMax 190; Molecular De-
vices Corp., Sunnyvale, CA), and subtraction of nonspecific readings
(measured at 630 nm) was done automatically during the OD450
reading. To obtain the percentage of cell growth or cell viability,
the OD450 of the cells (in each time point of Dox treatment) was
divided by the OD450 of the cells at the initial time point of the
experiment. For DFX-treated cells, percentage of cell viability was
calculated by dividing the OD450 of these cells by OD450 of the
untreated cells.
Statistical Analysis
Unpaired Student’s t test was used to compare in vitro results. Sur-
vival analysis was computed by the Kaplan-Meier method and com-
pared by the log-rank test. Fisher’s exact test was used to compare
number of mice with lung metastasis.
Results
Generation of Local and Metastatic NB Variants
It was previously demonstrated that orthotopic inoculation of NB
cells produces a more relevant model than a heterotopic inoculation
[14]. The orthotopic NB model has the advantage of reflecting more
accurately the biology of the local primary tumor and of the metas-
tases including the interactions of the tumor cells with their micro-
environment. Similar interactions occur in pediatric patients with
adrenal NB [14].
Neuroblastoma cells from the SH-SY5Yor MHH-NB-11 cell lines
were injected into the left adrenal gland of athymic nude mice. The
animals were examined weekly, and laparotomy was performed when
animals showed terminal signs (swelling of the abdomen, protrude
left adrenal tumor, and reduced body mass).
The local tumors were harvested to yield the local variants: SY5Y.
Ad and MHH.Ad. Lung metastases were harvested from lungs of
tumor-bearers and reestablished in culture. Cells from these cultures
were reinjected into the adrenal gland of another set of athymic nude
mice. After two to three such inoculation cycles, the metastatic variants
SY5Y.Lu2 and MHH.Lu3 were established in culture (Figure 1).
To determine whether the isolated variants had increased meta-
static potential, cells from the local and the metastatic variants were
inoculated orthotopically into nude mice. Histopathology detected
lung metastases in 5 of 8 mice inoculated with the metastatic variant
SY5Y.Lu2 and in 5 of 11 mice inoculated with the metastatic variant
MHH.Lu3. None of the local variants produced lung metastases in
the injected mice (Table 1). Bone marrow metastases were not de-
tected by histopathology.
Preliminary data showed that inoculation of SY5Y.Lu2 and
MHH.Lu3 into the adrenal gland of nude mice produced lung and
bone marrow micrometastases (detected by the successful isolation
of tumor cells from the lung and bonemarrow of tumor-bearing mice).
The original SH-SY5Y or MHH-NB-11 cell lines, as well as the
local and the metastatic variants from these lines, were tested for
their aggressiveness (i.e., the time interval during which a given in-
oculum of cells kills the host). The cells were injected into the adre-
nal gland of nude mice, and the mice were killed when moribund
(63–247 days after inoculation). All cell variants were tumorigenic
after orthotopic inoculations (Table 1). The median survival time
after the intra-adrenal injection of SH-SY5Y, SY5Y.Ad, or SY5Y.Lu2
cells was 116, 109, and 80 days, respectively (Figure 2A). The me-
dian survival time after the intra-adrenal injection of MHH-NB-11,
MHH.Ad, or MHH.Lu3 cells was 139, 110, and 86 days, respectively
(Figure 2B). These results demonstrate that in vivo passaged tumor
cells are more aggressive than the corresponding cultured ones con-
firming previous studies [27] and that the metastatic variants are more
aggressive than the corresponding local tumor variants.
Characterization of Local and Metastatic NB Variants
Immunophenotyping and karyotyping of local and metastatic
variants of NB. We next phenotyped the local and metastatic var-
iants with double-color flow cytometry. All of the variants strongly
expressed human CD56 [28], HLA class I, and did not express
mouse H-2 class I (Figure 3). These results confirmed the identity
of the tumor variants as human NB cells.
The variants were analyzed with a broad panel of antibodies
against cell surface antigens by flow cytometry. The local and the met-
astatic variants of both the SH-SY5Y and the MHH-NB-11 systems
showed a similar expression pattern of the NB prognostic antigens
TRK A, TRK B, CXCR4, CD44, and MRP-1 [2]. Similar results
were obtained with CX3CL1, CX3CR1, and CXCR3. These chemo-
kines and chemokine receptors represent markers that may be rele-
vant to NB progression [29] (Nevo et al., unpublished observations).
A cytogenetic study did not detect differences between the local
and metastatic variants of the MHH tumor in structural chromo-
somal rearrangements, including in homogeneously staining regions
representing genomic amplification of MYCN and t(1;17) transloca-
tions (Figure W1). This indicated that no additional chromosomal
aberrations were acquired by the metastatic variant beyond those that
existed in the local variant.
Differential drug sensitivity of local and metastatic variants of
NB. The local and the metastatic variants as well as the parental
cell lines did not differ in their proliferative capacity in vitro under
normal culture conditions (in serum-containing medium).
We next analyzed the viability of the cell variants in the presence of
Dox, a chemotherapeutic agent commonly used in the treatment of
NB [30]. MHH.Ad and MHH.Lu3 were cultured in the presence
of 1 μM Dox for up to 96 hours. As expected, the MHH.Lu3
metastatic variant exhibited a significantly higher resistance to
Dox than the local variant. After 48 hours of exposure to Dox,
the average cell viability was 19 ± 7% and 55 ± 6%, respectively
(P < .001). This effect was more pronounced with 1 μM than with
0.5 μM Dox.
Because 1 μM Dox caused a massive cell death in both SY5Y var-
iants, we decreased the concentration of Dox to reveal a differential
drug sensitivity of local and metastatic variants if existing. SY5Y.Ad
and SY5Y.Lu2 variants were cultured in the presence of 0.125 μM
Dox for up to 96 hours. In contrast to the MHH variant system,
Dox was significantly more toxic to the metastatic variant than to
the local variant (higher concentrations of Dox were toxic to both
of the variants). The average cell viability after 48 hours was 57 ±
6% for the local variant and 20 ± 11% for the metastatic variant
(P < .05). Similar results were obtained after 24 hours of exposure
to Dox.
Deferoxamine, an iron chelator, is a hypoxia mimetic agent that
up-regulates HIF-1α and certain inflammatory mediators. Deferox-
amine was shown to exhibit antiproliferative properties in human
NB cell lines [31,32]. Deferoxamine alone, or in combination with
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other cytotoxic agents, is often used as an antiproliferative agent in
patients with NB [33,34].
The SY5Y.Ad, SY5Y.Lu2, MHH.Ad, and MHH.Lu3 variants
were cultured in the presence of 0, 25, 50, and 100 μM DFX for
24 hours. The MHH metastatic variant displayed significant re-
sistance to DFX compared to the corresponding local variant. The
average cell viability was obtained as described in the Materials and
Methods section. The viability of the local variant cells was 90 ± 10%
(25 μM DFX), 80 ± 15% (50 μM DFX), and 76 ± 8% (100 μM
DFX) compared to 119 ± 7% (25 μM DFX; P < .01), 119 ± 12%
(50 μM DFX; P < .05), and 106 ± 16% (100 μM DFX; P < .05) of
the viable cells in the metastatic variant.
Figure 1. The in vivo generation of local and metastatic human NB variants. (A) Neuroblastoma cells from the SH-SY5Y or MHH-NB-11
cell lines were injected into the left adrenal gland of athymic nude mice. The local tumors, SY5Y.Ad and MHH.Ad, were harvested and
established in culture. Lung metastases were harvested, and tumor cells were reinjected into the adrenal gland of another set of athymic
nude mice. The cycles were repeated one or two additional times to yield the metastatic variants, SY5Y.Lu2 and MHH.Lu3, respectively.
(B) Orthotopic injection of NB cells into the left adrenal gland, as described in the Materials and Methods section. (C) A local (adrenal)
tumor harvested from a xenografted mouse. The local tumors in most of the animals were bulky and surrounded the left kidney. (D)
Parental cell lines, local and metastatic variants used in this study.
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Similar results were obtained with the SY5Y variants (data not
shown). Overall, DFX was toxic to both local variants but not to
the metastatic variants.
Morphology and migratory capacity of local and metastatic variants
of NB. Figure 4, A and B, demonstrates that the local and the met-
astatic variants of both the SH-SY5Y and MHH-NB-11 cells present
distinct cell morphologies. The local variants resemble the cultured pa-
rental cell lines. These cells have a neuroblastic phenotype, a small,
round cell body that may have short neuritic processes and grow as
poorly attached aggregates. In contrast, the metastatic variants are
morphologically flattened, moderately adherent with relatively long
neuritic processes that are growing mostly in monolayer.
Enhanced cell migration is associated with and leads to metastasis.
Therefore, we compared the migratory ability of the local and the met-
astatic variants. The wound healing assay showed that after 24 to
72 hours, the metastatic SY5Y.Lu2 variant had a significantly higher
rate of wound closure compared to the local variant (Figure 4C ).
Figure 4D demonstrates that in the MHH.Lu3 metastatic variant,
there is a population of cells that migrated into the gap already after
24 hours. This population continued to migrate into the gap in the
next 48 hours of the experiment. This migratory cell population was
absent in the local MHH.Ad variant. The closure of the wound by
these cells after 72 hours seems to be due to cell proliferation and not
to increased motility.
Secretion ofMMP-2 andMMP-9 from local and metastatic variants
of NB. Matrix metalloproteinases are a phenotypic characteristic of
malignant cancer cells that function as promalignancy factors. These
tumor-derived enzymes support the invasion of tumor cells through
the basement membrane [35]. Matrix metalloproteinases antagonize
apoptosis, orchestrate angiogenesis, and regulate innate immunity, re-
sulting in tumor dissemination and metastasis [36].
Gelatin zymography was used to determine the activity of gelatin-
ases (MMP-2 and MMP-9) in the cell variants. It was shown that
the metastatic variant SY5Y.Lu2 displayed a relatively higher activity
level of the two gelatin-degrading enzymes (∼66 and ∼92 kDa) than
the parental SH-SY5Y cells and the local SY5Y.Ad variant. All the cell
variants of the MHH system produced only the ∼66-kDa enzyme at
a similar level of activity (data not shown). Using antibodies directed
against MMP-2 and MMP-9, we identified the above proteolytic en-
zymes as the active form of MMP-2 and the proMMP-9.
Expression of HIF-1α by local and metastatic variants of NB.
Hypoxia, a common feature of solid tumors, exerts gene regulatory
activities and selective pressures on tumor cells that drive their pro-
gression. Oxygen homeostasis is predominantly controlled by the
transcriptional activator HIF-1 within the cell. Whereas the beta sub-
unit of this heterodimeric factor is oxygen-independent, the alpha
subunit HIF-1α is stable and active only in the absence of oxygen
[37]. Under hypoxia, HIF induces or represses numerous genes that
control multiple cell functions involved in tumor growth, progres-
sion, invasion, and metastasis [38]. As mentioned previously, DFX is
an iron chelator that up-regulates HIF-1α and thus mimics hypoxia
conditions in culture [31,32].
To determine whether HIF-1α is differentially expressed in the local
and the metastatic variants of NB, we treated the cells with 0, 25,
and 50 μM DFX for 24 hours and analyzed HIF-1α protein ex-
pression using Western blot analysis. As shown in Figure 5, 25 or
50 μM of DFX induced an increase of HIF-1α expression in all
the variants. At both concentrations of DFX, the expression of
HIF-1α was higher in the metastatic variants of the SY5Y and
MHH systems compared to the corresponding local variants.
Because HIF-1α confers on cells the ability to cope with hypoxic
stress [37], it is expected that the metastatic variants would more
readily up-regulate the expression of HIF-1α than the nonmetastatic
ones when exposed to hypoxia mimetic conditions.
Table 1. Tumorigenicity and Metastasis Formation in Nude Mice by Local and Metastatic Human
Neuroblastoma Variants.






No. Mice with Bone
Marrow Metastasis*
SY5Y.Ad 100 0/6 0/7
SY5Y.Lu2 100 5/8 0.03† 0/9
MHH.Ad 100 0/12 0/7
MHH.Lu3 100 5/11 0.01‡ 0/11
Nude mice were injected into the adrenal gland with 1 × 106 cells. The mice were killed when
moribund and necropsied. The presence of local (adrenal) tumor was determined.
Lung and sternum sections were stained with hematoxylin and eosin and evaluated by light mi-
croscopy for the presence of metastases.
*Number of tumor-positive mice per number of inoculated mice.
†Versus SY5Y.Ad.
‡Versus MHH.Ad.
Figure 2. Survival curves of nude mice bearing local andmetastatic
variants of NB. Local and metastatic variants of NB were inoculated
orthotopically into the adrenal gland of nude mice. Kaplan-Meier
survival curve shows that the survival of mice bearing the meta-
static variant: SY5Y.Lu2 (A) or MHH.Lu3 (B) was significantly short-
er than that ofmice bearing tumors generated by the corresponding
local variant or the parental cell line. (Log-rank statistic: SH-SY5Y
versus SY5Y.Lu2, P < .01; SY5Y.Ad versus SY5Y.Lu2, P < .01;
MHH-NB-11 versus MHH.Lu3, P < .05).
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The association between increased HIF-1α expression and in-
creased metastatic potential is supported by clinical correlation be-
tween increased HIF-1α expression and increased patient mortality
in several types of cancer [39].
Discussion
Metastasis develops when genetically unstable cancer cells adapt to
a tissue microenvironment that is distant from the primary tumor.
The metastatic process involves several sequential, interrelated, and
rate-limiting inductive and selective steps. It exploits both the se-
lection of intrinsic beneficial properties of tumor cells and the si-
multaneous recruitment of host microenvironmental properties
that support invasion, angiogenesis, and other promalignancy func-
tions of metastatic tumor cells [11]. Thus, metastasis can be de-
scribed as a process that emerges from the somatic evolution of a
genetically diversified cancer cell population under the selective pres-
sures of an environment that imposes tight rules on cell behavior [9].
The generation of tumor cell populations that differ in their meta-
static ability is a gradual process, requiring several cycles of in vivo
passages, as was shown previously in several studies [20,27,40].
Neuroblastoma tumors are heterogeneous tumors derived from
the neural crest [41]. Metastasis is the leading cause of death of NB
patients, and despite substantial recent progress [10], we still have to
broaden our understanding of NB metastasis.
Neuroblastoma disseminates most frequently to bone marrow
(87%) and to bone (66%) [4,5,41]. Neuroblastoma pulmonary me-
tastases are rare at diagnosis and represent a terminal stage [6–8,41].
Kammen et al. [8] reported that although some NB patients with
lung metastasis responded to treatment, all patients died of relapse
in the lung or of progressed lung disease.
These data compelled us to focus specifically on lung metastasis
that may reflect more biologically aggressive cells and portends a
poor prognosis.
The cellular and molecular events leading to NB metastasis are
largely unexplored. One of the reasons for this is the lack of rele-
vant and reliable human xenograft animal models. In this study,
we filled this gap by developing an in vivo model for NB metastasis,
thereby providing an unlimited source for cells representing local and
metastatic NB. This model is a critical tool for future studies on
NB metastasis.
We describe the generation and characterization of two novel hu-
man NB xenograft models, each comprising a local tumor variant
and a lung metastatic variant. Two NB cell lines were used to develop
these variants: the SH-SY5Y cell line, a subclone derived from the
SK-N-SH cell line that was established from a bone marrow biopsy,
and the MHH-NB-11 cell line, derived from a tumor mass involving
the adrenal gland [23,24]. Cells from both lines were injected ortho-
topically into the adrenal gland of nude mice. The local encapsulated
tumor and lungs suspected of containing metastatic lesions were har-
vested, and the tumor cells were recovered in culture. Lung meta-
static tumor cells were then reinjected into the adrenal gland of
another set of nude mice. After two to three inoculation cycles, we
established local tumor variants and lung metastatic variants of both
NB cell lines.
By using this procedure, we probably induced a metastatic pheno-
type in the originally nonmetastatic MHH tumor and increased the
metastatic phenotype of the SY5Y tumor.
Figure 3. Immunophenotyping of local and metastatic NB variants. Flow cytometric analyses of the NB local variants, SY5Y.Ad (a, b) and
MHH.Ad (e, f), and the NB metastatic variants, SY5Y.Lu2 (c, d) and MHH.Lu3 (g, h), using monoclonal antibodies against CD56/HLA/H-2.
Cells were positive for HLA and CD56 but negative for H-2. Percentages of CD56+/HLA+/H-2− were calculated by using the following
gating strategy. On a FL1-H/FL2-H dot plot, the CD56+/H-2− cells were identified by region R1. In a second dot plot, region R1 was
defined CD56+/H-2−, and region R2 was used to identify the CD56+/HLA+ human NB cells.
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The human NB nature of the cells was confirmed by a strong pos-
itive expression for human CD56 [28], and HLA class I and by lack
of expression of mouse H-2 class I.
The phenotype and the behavior of the metastatic variants were
compared to those of the local tumor variants. All the variants were
tumorigenic after an orthotopic injection into the adrenal gland of
nude mice. The SY5Y.Lu2 variant, which was derived after two
transplantation cycles in vivo, produced lung metastasis in 60%
of inoculated mice, and the MHH.Lu3, derived after three trans-
plantation cycles in vivo, produced lung metastasis in 45% of in-
oculated mice. The local variants from both tumor systems did not
produce metastasis.
Figure 4. Distinct cell morphologies and migratory capacity of local and metastatic NB variants in vitro. Morphology of (A) SH-SY5Y (a, b),
SY5Y.Ad (c, d), and SY5Y.Lu2 (e, f). Morphology of (B) MHH-NB-11 (a, b), MHH.Ad (c, d), and MHH.Lu3 (e, f). Phase contrast photomicro-
graphs: a, c, and e original magnification, ×10; b, d, and f original magnification, ×40. Phase contrast photomicrographs of scratched
monolayers in a wound healing assay: SY5Y.Ad and SY5Y.Lu2 variant cells (C) and MHH.Ad and MHH.Lu3 variant cells (D) at 0, 24, 48,
and 72 hours. Shown are representative photomicrographs (original magnification, ×10) of two to three independent experiments.
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Although the SY5Y.Lu2 and MHH.Lu3 variants did not produce
bone marrow metastases, ongoing experiments indicate that the
orthotopic inoculation of these variants into the adrenal gland of
nude mice produced bone marrow micrometastases in the inoculated
mice. The presence of micrometastases, which might escape morpho-
logic identification during the histopathologic analysis, suggests that
tight microenvironmental conditions in murine bone marrow can
suppress the formation of NB macrometastases at this site.
The metastatic variants were flattened with relatively long neuritic
processes, were moderately adherent, and mostly grow as monolayers.
Morphologically, these cells resemble the human NB intermediate-
type (I-type) cells, which exhibit biochemical features of both neuro-
blastic (N) cells and substrate-adherent (S) cells [42,43]. Neuroblastoma
I-type cells are multipotent embryonic precursor cells of the periph-
eral nervous system. We postulated, therefore, that similar to these
cells, the metastatic variants are highly tumorigenic and are capable
of self-renewal, proliferation, and further differentiation [42].
Whereas the proliferative capacity of the local and the metastatic
variants was essentially identical under normal culture conditions,
these variants differ in their sensitivity to the apoptosis-inducing
agent doxorubicin.
Keshelava et al. [44] demonstrated that chemotherapeutic agents
given to NB patients can confer an in vivo selection pressure, which
leads to resistance to cytotoxic drugs. However, because both the
MHH-NB-11 and the SH-SY5Y cell lines were established from
NB patients that showed no response to chemotherapy, this cannot
explain our results [24,45].
Our findings, however, can be explained by Fidler’s clonal paradigm
indicating that metastatic lesions are not necessarily uniform with re-
spect to certain biologic properties [46]. In this regard, Spengler et al.
[47] demonstrated a differential drug sensitivity of two subclones
(SH-SY5Y and SH-EP) derived from the human NB cell line
SK-N-SH. Our study reveals that although the in vivo–generated
NB metastatic variants expressed a metastatic phenotype, they ex-
hibited a diverse response to doxorubicin. The question of whether
the differential chemoresistance observed in this study is related to spe-
cific molecular or metabolic alterations associated with the in vivo pro-
cedure per se remains to be established.
Enhanced cell migration and increased proteolytic enzyme activity
are promalignancy characteristics [48]. Our results indicate that the
SY5Y metastatic variant migrated significantly faster and that its
MMP-2 and MMP-9 activity was higher than the local variant. In-
deed, increased activity of MMP-2 and MMP-9 has been reported to
occur in patients with advanced NB [49,50]. Similar results were not
obtained with the MHH cells. The possibility cannot be excluded
that the repeated in vivo pressures (selection, adaptation, and in-
duction) led to the isolation of a population of metastatic cells that
express and release proteolytic enzymes, not tested in this work
[35,51]. Such enzymes could contribute to their enhanced motility
and invasion in vivo and in vitro.
Our previous study suggested that CXCR4 is involved in the for-
mation of NB bone marrow metastases [52]. Expression of functional
CXCR4 was further described to confer a distinct gene expression pro-
file on neuroblastoma cells [53]. Tumor cells that arrive at their tar-
get organ are exposed to various factors expressed at this site. These
factors promote or restrict their adhesion, invasion, and proliferation.
Thus, the expression of functional receptors by the tumor cells that
arrive at the metastatic site and the equilibrium between the cor-
responding factors may affect the fate of the metastatic process [29].
To further test this assumption, we tested the expression of several che-
mokine receptors in our variant systems. The local tumor cell variants
as well as the metastatic variants were found to express similar levels
of these receptors. The lack of difference in chemokine receptor ex-
pression between the metastatic and nonmetastatic variants can be
explained by the results of Holland et al. [54]. A differential CXCR4-
mediated chemotaxis was seen in a range of breast cancer cell lines cov-
ering a spectrum of invasive phenotypes, whereas the expression levels
of CXCR4 were uniform across the entire panel, only highly invasive
Figure 5. Induction of HIF-1α in local and metastatic NB variants by the hypoxia mimetic DFX. (A) SY5Y.Ad and SY5Y.Lu2 variant cells
and (B) MHH.Ad and MHH.Lu3 variant cells were treated with 0, 25, and 50 μM DFX for 24 hours. HIF-1α and ERK2 (loading control)
expression was detected by Western blot analysis. Presented are the results of one representative blot and its densitometry analysis of
four independent experiments.
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cells expressed functional receptors [54]. In another study, Palmesino
et al. [55] showed that B cells in all stages of maturation exhibit similar
expression levels of CXCR4. However, mature B cells exhibit a re-
duced activity of this receptor. This reduction in activity could be
the result of a biochemical mechanism [55]. We speculate that simi-
larly to breast cancer cells and B cells, local and metastatic NB cells
express similar levels of CXCR4, CX3CR1, and CXCR3 throughout
the metastatic process but may express a differential functional activ-
ity of these receptors. Specific chemokine receptor–associated proteins
or changes in glycosylation patterns may be responsible for the fine-
tuning of receptor-mediated responses.
Hypoxia, a common characteristic of the microenvironment of
solid tumors, activates HIF-1α, a transcription factor and a key ele-
ment for several signaling pathways in hypoxic tissues as well as in
tumor cells [37,38]. In this study, we demonstrated that under hypoxia
mimetic conditions, the expression of HIF-1α in the metastatic var-
iants was higher than its expression in the local variants. Thus, HIF-1α
probably plays a significant role in conferring a high-malignancy
phenotype on the SY5Y.Lu2 and MHH.Lu3 metastatic NB variants.
This supports the results of previous studies showing that HIF-1α is a
metastasis-regulating gene, and its activities are strongly linked to in-
vasion, angiogenesis, and tumorigenesis [37,38]. Deferoxamine has
been shown to induce the activity of HIF-1α in a manner similar to
the induction of HIF-1 by hypoxia [56].
Although DFX functions as an antiproliferative agent for the treat-
ment of NB patients [33,34], it can also function as a proinvasive factor
[57]. Indeed, DFX-treated metastatic variants exhibited an increased
proliferation capacity compared to DFX-treated local variants. Sullivan
and Graham [58] suggested that the acquisition of the metastatic phe-
notype is not simply the result of disregulated signal transduction
pathways but is achieved through a stepwise process driven by multiple
hypoxia-inducible mechanisms, such as intravasation, motility, and
extravasation. Furthermore, tumor cells in a hypoxic environment un-
dergo adaptive changes that allow them to survive and proliferate.
Taken together, the establishment of a reproducible orthotopic
model of human NB metastasis offers an unlimited source for mate-
rial amenable for transcriptomic and proteomic analyses. The above
data and the requisite of an effective NB treatment accentuate the
need to concurrently understand the metastatic process as well as
the phenotypic diversity of NB metastasis.
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Figure W1. Representative karyotypes of the parental cell line MHH-NB-11 (A), the local variant MHH.Ad (B), and the metastatic variant
MHH.Lu3 (C).
Figure W1. (continued)
